American Journal of Epidemiology Vol. 154, No. 7 : 675-681
Copyright © 2001 by The Johns Hopkins University School of Hygiene and Public Health
ORIGINAL CONTRIBUTIONS |
Methods to Assess Population Effectiveness of Therapies in Human Immunodeficiency Virus Incident and Prevalent Cohorts
1 Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD.
2 Department of Medicine, University of Pittsburgh, and VA Medical Center, Pittsburgh, PA.
3 School of Medicine, Northwestern University, Chicago, IL.
4 School of Public Health, University of California, Los Angeles, CA.
Two methods are presented for measuring population effectiveness (i.e., reduction of disease in a population in which only some receive treatment) of antiretroviral therapy among human immunodeficiency virus (HIV)-infected men at risk for acquired immunodeficiency syndrome (AIDS) and followed between January 1, 1986, and June 30, 1999, in the Multicenter AIDS Cohort Study. Method I, requiring use of a seroincident cohort, estimates relative hazards of AIDS for persons at equal duration of infection. Method II, allowing use of a seroprevalent cohort, estimates relative hazards since the beginning of therapy eras for persons starting at equal levels of prognostic markers of disease stage (CD4 cell count and HIV type 1 RNA). The follow-up interval was divided into four calendar periods to characterize different eras of antiretroviral therapy. For method I, the relative hazards were 1.52 (95% confidence interval (CI): 0.93, 2.49), 0.91 (95% CI: 0.66, 1.26), and 0.30 (95% CI: 0.18, 0.51) for the eras of no therapy, dual nucleoside therapy, and potent combination antiretroviral therapy, respectively (monotherapy was the reference era). For method II, the corresponding relative hazards were 1.52 (95% CI: 1.10, 2.09), 1.03 (95% CI: 0.77, 1.38), and 0.31 (95% CI: 0.21, 0.45). These results extend the measurement of population effectiveness from incident to prevalent cohorts and demonstrate the ability of cohort studies to complement information provided by clinical trials.
acquired immunodeficiency syndrome; cohort studies; epidemiologic methods; HIV
Abbreviations: AIDS, acquired immunodeficiency syndrome; HIV, human immunodeficiency virus
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H Lopez-Gatell, S. Cole, N. Hessol, A. French, R. Greenblatt, S Landesman, S Preston-Martin, and K Anastos Effect of Tuberculosis on the Survival of Women Infected with Human Immunodeficiency Virus Am. J. Epidemiol., May 15, 2007; 165(10): 1134 - 1142. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Biggar, E. S. Jaffe, J. J. Goedert, A. Chaturvedi, R. Pfeiffer, E. A. Engels, and for the HIV/AIDS Cancer Match Study Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS Blood, December 1, 2006; 108(12): 3786 - 3791. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. E. Cain, S. R. Cole, J. S. Chmiel, J. B. Margolick, C. R. Rinaldo Jr., and R. Detels Effect of Highly Active Antiretroviral Therapy on Multiple AIDS-defining Illnesses among Male HIV Seroconverters Am. J. Epidemiol., February 15, 2006; 163(4): 310 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Chou, L. H. Huffman, R. Fu, A. K. Smits, and P. T. Korthuis Screening for HIV: A Review of the Evidence for the U.S. Preventive Services Task Force Ann Intern Med, July 5, 2005; 143(1): 55 - 73. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. P. Giordano, J. R. Kramer, J. Souchek, P. Richardson, and H. B. El-Serag Cirrhosis and Hepatocellular Carcinoma in HIV-Infected Veterans With and Without the Hepatitis C Virus: A Cohort Study, 1992-2001 Arch Intern Med, November 22, 2004; 164(21): 2349 - 2354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G de la Hera, I. Ferreros, J. del Amo, P. G. de Olalla, S. P. Hoyos, R. Muga, J. del Romero, R. Guerrero, I. Hernandez-Aguado, and and GEMES Gender differences in progression to AIDS and death from HIV seroconversion in a cohort of injecting dug users from 1986 to 2001 J. Epidemiol. Community Health, November 1, 2004; 58(11): 944 - 950. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D M Gibb, T Duong, P A Tookey, M Sharland, G Tudor-Williams, V Novelli, K Butler, A Riordan, L Farrelly, J Masters, et al. Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland BMJ, November 1, 2003; 327(7422): 1019. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Samet Measuring the Effectiveness of Inhaled Corticosteroids for COPD Is Not Easy! Am. J. Respir. Crit. Care Med., July 1, 2003; 168(1): 1 - 2. [Full Text] [PDF]
|
|
|
|
 |
|
 Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks Int. J. Epidemiol., October 1, 2002; 31(5): 951 - 958. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. May Commentary: The changing face of AIDS Int. J. Epidemiol., October 1, 2002; 31(5): 959 - 960. [Full Text] [PDF]
|
|